Compass Therapeutics Inc (NASDAQ:CMPX) has a beta value of 1.28 and has seen 1.11 million shares traded in the last trading session. The company, currently valued at $412.08M, closed the last trade at $2.98 per share which meant it gained $0.06 on the day or 2.05% during that session. The CMPX stock price is -36.91% off its 52-week high price of $4.08 and 70.81% above the 52-week low of $0.87. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.69 million shares traded. The 3-month trading volume is 822.11K shares.
The consensus among analysts is that Compass Therapeutics Inc (CMPX) is Buy stock at the moment, with a recommendation rating of 1.10. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Sporting 2.05% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CMPX stock price touched $2.98 or saw a rise of 3.25%. Year-to-date, Compass Therapeutics Inc shares have moved 186.54%, while the 5-day performance has seen it change 12.45%. Over the past 30 days, the shares of Compass Therapeutics Inc (NASDAQ:CMPX) have changed 23.65%. Short interest in the company has seen 7.39 million shares shorted with days to cover at 9.27.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 50.33% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -101.34% off the targeted high while a plunge would see the stock gain -101.34% from current levels.
Compass Therapeutics Inc (CMPX) estimates and forecasts
The company’s shares have gained 68.36% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -104.70% over the past 5 years. Earnings growth for 2025 is a modest -39.17% while over the next 5 years, the company’s earnings are expected to increase by 8.37%.
CMPX Dividends
Compass Therapeutics Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
Insiders own 14.16% of the company shares, while shares held by institutions stand at 70.02% with a share float percentage of 81.57%. Investors are also buoyed by the number of investors in a company, with Compass Therapeutics Inc having a total of 138.0 institutions that hold shares in the company. The top two institutional holders are ORBIMED ADVISORS LLC with over 22.36 million shares worth more than $22.36 million. As of 2024-06-30, ORBIMED ADVISORS LLC held 16.2534% of shares outstanding.
The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 11.13 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.13 million and represent 8.0893% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 5.01% shares in the company for having 2.61 shares of worth $7.78 million while later fund manager owns 2.61 shares of worth $7.76 million as of May 31, 2025 , which makes it owner of about 5.00% of company’s outstanding stock.
